<DOC>
	<DOCNO>NCT01483625</DOCNO>
	<brief_summary>The aim study investigate whether early introduction maintenance bronchodilator therapy acute symptomatic episode disease show benefit recovery symptom . It also represent opportunity identify COPD patient earlier disease state start maintenance therapy , appropriate .</brief_summary>
	<brief_title>Tiotropium ( 18mcg ) Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Respiratory Infection</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient must sign informed consent consistent International Conference Harmonization Good Clinical Practice ( ICHGCP ) guideline prior participation trial conduct study procedure . 2 . Male female patient 40 year age old . 3 . Ability independently read understand English and/or Spanish . 4 . Any selfreported history smoking ( e.g . = 100 cigarette ( ~5 pack ) lifetime ) . 5 . Acute respiratory symptom 7 day 6 . All patient must diagnosis COPD , must airway obstruction postbronchodilator ( Forced Expiratory Volume 1 second ( FEV1 ) /Forced Vital Capacity ( FVC ) ) &lt; 0.7 . The diagnosis COPD make Visit 1 . 7 . The clinical assessment enrol patient judgement investigator support introduction COPD maintenance therapy . 8 . Patients must able inhale medication competent manner HandiHaler速 device meter dose inhaler ( MDI ) Exclusion criterion : 1 . Therapy longacting bronchodilator , shortacting anticholinergic , inhale corticosteroid regular maintenance use ( &gt; 14 consecutive day ) systemic corticosteroid ( latter respiratory indication ) previous 6 month ( short course systemic corticosteroid 14 day respiratory indication allow ) ; case use systemic corticosteroid medication respiratory condition , exclusion unstable dos ( i.e. , less six week stable dose ) dose excess equivalent 10 mg prednisoloneequivalent per day . In addition , daily use shortacting beta2agonist week prior Visit 0 allow . The following exclusion criterion apply Visit 1 : 2 . Significant disease COPD . A significant disease define disease condition , opinion investigator , may put patient risk participation study may influence patient多s ability participate study . 3 . A recent history ( i.e. , six month less ) myocardial infarction . Patients stable history cardiac stent prior six month permit . 4 . Any unstable lifethreatening cardiac arrhythmia require intervention change drug therapy last year . 5 . Hospitalisation cardiac failure ( New York Heart Association ( NYHA ) Class III IV ) past year . 6 . Any significant new ECG finding V1 judge investigator , include , limited sign ischemia , arrhythmia , heart failure , report chest pain . 7 . Known active tuberculosis . 8 . Current asthma ( patient treat asthma last 2 year ) , cystic fibrosis , clinical diagnosis bronchiectasis , interstitial lung disease , pulmonary thromboembolic disease . 9 . A history thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion criterion . 2 . 10 . Malignancy patient undergone resection , radiation , chemotherapy biological treatment within last year currently active radiation therapy , chemotherapy biological treatment . Patients treat basal cell carcinoma allow . 11 . At visit 0 1 , severe respiratory infection , e.g . pneumonia ( suspected investigator ) , condition exacerbation require ER visit hospitalization , need oxygen treatment . 12 . Known hypersensitivity anticholinergic drug , lactose , component HandiHaler速 MDI inhalation solution delivery system . 13 . Treatment restrict pulmonary medication 14 . Requirement supplemental oxygen therapy = 24 hour previous 6 month . 15 . Known moderate severe renal impairment . 16 . Known narrow angle glaucoma . 17 . Significant symptomatic prostatic hyperplasia bladderneck obstruction . Patients whose symptom control treatment may include . 18 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( i.e. , oral contraceptive , intrauterine device , diaphragm subdermal implant e.g. , Norplant速 ) least three month prior duration trial . 19 . Significant alcohol drug abuse within past 12 month . 20 . Actively participate pulmonary rehabilitation program . 21 . Previously randomize study currently participate another interventional study . 22 . Visual impairment judge investigator allow patient independently read complete questionnaire electronic diary ( eDiary ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>